Peripheral Neuropathy Treatment Market
Global Peripheral Neuropathy Treatment Market Size, Share & Trends Analysis Report, By Type (Antidepressants, Pain Relievers, Antiseizure, and Others), By Application (Diabetes, Chemotherapy-Induced, and Others) and Forecast, 2020-2026
The global peripheral neuropathy treatment market is estimated to grow at a CAGR of 4.3% during the forecast period. The increasing prevalence of diabetes and cancer and rising launches of generic versions of peripheral neuropathy drugs are some pivotal factors accelerating market growth. As per the International Diabetes Federation (IDF), in 2019, nearly 463 million adults (20-79 years) were suffering from diabetes, which is expected to reach 700 million by 2045. The most common diabetic complication is peripheral neuropathy. It is a severe diabetic complication that may affect nearly 50% of people suffering from diabetes. This condition affects the legs and feet first and is followed by hands and arms.
Several prescription medications are available for diabetes-associated nerve pain. Some antidepressants provide ease to nerve pain. Tricyclic antidepressants may support mild to moderate nerve pain. This class of drugs includes imipramine (Tofranil), amitriptyline, and desipramine (Norpramin). With the increasing prevalence of diabetic neuropathy, some new launches of generic peripheral neuropathy drugs have been reported over the years. For instance, in July 2019, Rising Pharmaceuticals, Inc. declared the US launch of a generic version of Lyrica (pregabalin) capsules. These are available in eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg).
Pregabalin capsules are designated for the treatment of neuropathic pain related to diabetic peripheral neuropathy, for the neuropathic pain management associated with spinal cord injury, for the management of fibromyalgia, for postherpetic neuralgia management, and for adjunctive therapy to treat partial-onset seizures in patients 4 years of age and older. The launch of generic drugs is offering a cost-effective treatment alternative for patients suffering from debilitating neuropathic pain conditions. This, in turn, will provide growth opportunities for the market.
Market Segmentation
The global peripheral neuropathy treatment market is segmented based on type and application. Based on type, the market is classified into antidepressants, pain relievers, antiseizure, and others. Based on the application, the market is classified into diabetes, chemotherapy-induced, and others.
Rising Demand for Chemotherapy-Induced Peripheral Neuropathy Treatment
Peripheral nerve disorders are common complications associated with chemotherapy and some other drug therapies. With the increasing discovery of more and more effective therapies for cancer, the complications of peripheral neuropathy are growing in prevalence. Chemotherapy may lead to the degeneration of motor nerves and peripheral sensory. It has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. Chemotherapy-induced peripheral neuropathy is normally treated with analgesics, antidepressants, and anticonvulsants. Topical agents including lidocaine are often used, and opioids can also be used in cases that involve extreme pain.
Global Peripheral Neuropathy Treatment Market Share by Application, 2019 (%)
Regional Analysis
Geographically, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America is anticipated to hold a potential share in the market owing to the increasing prevalence of diabetes and rising demand for chemotherapy in the region. As per the American Diabetes Association, in 2018, 34.2 million or 10.5% of the American population were living with diabetes. Nearly half of all diabetic patients have some form of nerve damage. Therefore, peripheral neuropathy is the most common complication found in diabetic patients. As a result, there is an emerging demand for peripheral neuropathy treatment associated with diabetes in the region.
Global Peripheral Neuropathy Treatment Market Growth, by Region 2020-2026
Market Players Outlook
Some prominent players in the market include Pfizer Inc., Grünenthal GmbH, Novartis International AG, Eli Lilly and Co., and Daiichi Sankyo Co. Ltd. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in July 2020, Grünenthal declared that its subsidiary Averitas Pharma, Inc. gained US FDA approval for QUTENZA (capsaicin) 8% patch to treat neuropathic pain related to diabetic peripheral neuropathy of the feet in adults. It is a topical, non-opioid pain, and non-systemic treatment that is delivered in the patch form. It is the first and only treatment of its kind that delivers prescription-strength capsaicin directly into the skin. The patch can offer sustained relief for up to three months. It has no known drug-drug interactions. Its adverse reactions comprise application site reactions, such as pruritus, erythema, and pain.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global peripheral neuropathy treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules and Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Pfizer, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Grünenthal GmbH
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Novartis International AG
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Eli Lilly and Co.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Daiichi Sankyo Co. Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Peripheral Neuropathy Treatment Market by Type
5.1.1. Antidepressants
5.1.2. Pain Relievers
5.1.3. Antiseizure
5.1.4. Others
5.2. Global Peripheral Neuropathy Treatment Market by Application
5.2.1. Diabetes
5.2.2. Chemotherapy-Induced
5.2.3. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Achelios Therapeutics, Inc.
7.2. Acorda Therapeutics, Inc.
7.3. Alembic Pharmaceuticals, Ltd.
7.4. Amneal Pharmaceuticals LLC
7.5. Apotex, Inc.
7.6. Assertio Therapeutics, Inc.
7.7. Bristol Myers Squibb Co.
7.8. Cipla, Ltd.
7.9. Daiichi Sankyo Company, Ltd.
7.10. Eli Lilly and Co.
7.11. GlaxoSmithKline plc
7.12. Glenmark Pharmaceuticals, Ltd.
7.13. Grünenthal GmbH
7.14. Innovus Pharmaceuticals, Inc.
7.15. Johnson & Johnson Services, Inc.
7.16. Lupin, Ltd.
7.17. Mylan N.V.
7.18. Novartis International AG
7.19. Pfizer, Inc.
7.20. Teva Pharmaceutical Industries, Ltd.
1. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. GLOBAL ANTIDEPRESSANTS FOR PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL PAIN RELIEVERS FOR PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL ANTISEIZURE FOR PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL OTHER PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
7. GLOBAL DIABETIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
8. GLOBAL CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL PERIPHERAL NEUROPATHY TREATMENT IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
10. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
11. NORTH AMERICAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
12. NORTH AMERICAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
13. NORTH AMERICAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
14. EUROPEAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
15. EUROPEAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
16. EUROPEAN PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
17. ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
18. ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
19. ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
20. REST OF THE WORLD PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
21. REST OF THE WORLD PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE BY TYPE, 2019 VS 2026 (%)
2. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
3. GLOBAL PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
4. US PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
5. CANADA PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
6. UK PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
7. FRANCE PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
8. GERMANY PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
9. ITALY PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
10. SPAIN PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
11. ROE PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
12. INDIA PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
13. CHINA PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
14. JAPAN PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
15. REST OF ASIA-PACIFIC PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF THE WORLD PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
